LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

CEL-SCI Corp

Atvērts

SektorsVeselības aprūpe

0.22

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.21

Max

0.23

Galvenie mērījumi

By Trading Economics

Ienākumi

-964K

-7.1M

EPS

-0.096

EBITDA

-225K

-5.9M

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 14. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-23M

21M

Iepriekšējā atvēršanas cena

0.22

Iepriekšējā slēgšanas cena

0.22

Ziņu noskaņojums

By Acuity

86%

14%

367 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

CEL-SCI Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. maijs 22:52 UTC

Peļņas
Galvenie tirgus virzītāji

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025. g. 15. maijs 20:37 UTC

Top Ziņas
Peļņas

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025. g. 16. maijs 00:00 UTC

Tirgus saruna

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025. g. 15. maijs 23:47 UTC

Tirgus saruna

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025. g. 15. maijs 23:14 UTC

Top Ziņas

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025. g. 15. maijs 22:46 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 21:58 UTC

Peļņas

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 15. maijs 21:24 UTC

Peļņas

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025. g. 15. maijs 20:56 UTC

Tirgus saruna

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025. g. 15. maijs 20:54 UTC

Tirgus saruna
Peļņas

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025. g. 15. maijs 20:54 UTC

Peļņas

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025. g. 15. maijs 20:51 UTC

Peļņas

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025. g. 15. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. maijs 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025. g. 15. maijs 20:50 UTC

Peļņas

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025. g. 15. maijs 20:26 UTC

Top Ziņas

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025. g. 15. maijs 20:25 UTC

Peļņas

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CEL-SCI Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 0.2494Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

367 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.